To comprehensively quantify INHBA(+) CAFs during HGSOC progression, we performed INHBA ISH, α-SMA immunohistochemistry (IHC), and multiplex immunofluorescence (mIF; α-SMA, cytokeratin 8/18, CD3, CD4, CD8, and FOXP3) staining in a tissue microarray (TMA) consisting of matched primary, synchronous metastatic, and metachronous recurrent cancer samples from 42 HGSOC patients (Fig. 1a, Supplementary Fig. 6 and Supplementary Fig. 7). This evidence concerns the gene FOXP3 and cancer.